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Distinct subcellular localisations of the putative inositol 1,3,4,5-
tetrakisphosphate receptors GAP1IP4BP and GAP1m result from
the GAP1IP4BP PH domain directing plasma membrane targeting
P.J. Lockyer*, J.R. Bottomley*, J.S. Reynolds*, T.J. McNulty†, K. Venkateswarlu*,
B.V.L. Potter‡, C.E. Dempsey§ and P.J. Cullen*
Inositol 1,3,4,5-tetrakisphosphate (IP4), is a ubiquitous
inositol phosphate that has been suggested to function
as a second messenger. Recently, we purified and
cloned a putative IP4 receptor, termed GAP1IP4BP [1],
which is also a member of the GAP1 family of GTPase-
activating proteins for the Ras family of GTPases. A
homologue of GAP1IP4BP, called GAP1m, has been
identified [2] and here we describe the cloning of a
GAP1m cDNA from a human circulating-blood cDNA
library. We found that a deletion mutant of GAP1m, in
which the putative phospholipid-binding domains (C2A
and C2B) have been removed, binds to IP4 with a similar
affinity and specificity to that of the corresponding
GAP1IP4BP mutant. Expression studies of the proteins in
either COS-7 or HeLa cells showed that, whereas
GAP1IP4BP is located solely at the plasma membrane,
GAP1m seems to have a distinct perinuclear localisation.
By mutational analysis, we have shown that the contrast
in subcellular distribution of these two closely related
proteins may be a function of their respective pleckstrin
homology (PH) domains. This difference in localisation
has fundamental significance for our understanding of
the second messenger functions of IP4.
Addresses: *Laboratory of Molecular Studies on Cell Regulation,
Department of Biochemistry, School of Medical Sciences, University of
Bristol, Bristol BS8 1TD, UK. †Department of Pharmacology, University
of Cambridge, Tennis Court Road, Cambridge CB2 IBJ, UK. ‡School
of Pharmacy and Pharmacology, University of Bath, Claverton Down,
Bath BA2 7AY, UK. §Molecular Recognition Centre, Department of
Biochemistry, School of Medical Sciences, University of Bristol, Bristol
BS8 1TD, UK.
Correspondence: P.J. Cullen
E-mail: Pete.Cullen@bris.ac.uk
Received: 3 September 1997
Revised: 10 October 1997
Accepted: 10 October 1997
Current Biology 1997, 7:1007–1010
http://biomednet.com/elecref/0960982200701007
© Current Biology Ltd ISSN 0960-9822
Results and discussion
We isolated a full-length human GAP1m cDNA that con-
tained an open reading frame encoding a protein of 849
amino acids and a predicted molecular mass of 96.5 kDa.
The protein sequence is identical to that of the previously
cloned human GAP1m [2] with two exceptions: Ala216 is
replaced by a threonine and Ser646 is absent from our
sequence. There is 53.7% identity between GAP1IP4BP and
GAP1m at the protein sequence level and both contain
similar structural features, namely a highly conserved
GTPase-activating domain, C2A and C2B domains —
which, by analogy to synaptotagmin II, may serve as Ca2+-
dependent and Ca2+-independent phospholipid-binding
motifs, respectively — and a single pleckstrin homology
(PH) domain that includes a Bruton’s tyrosine kinase
(Btk) motif (Figure 1a) [3]. Although the important struc-
tural units and the carboxy-terminal tail show some
sequence divergence between GAP1IP4BP and GAP1m, a
major structural difference — at least at the level of the
primary sequence — is the alanine-rich 26 residue exten-
sion at the amino terminus of GAP1m (for an alignment of
these two proteins and details of the GAP1 family see [4]).
PH domains are important structural features of many sig-
nalling proteins that require either a direct plasma mem-
brane localisation or recruitment from the cytosol to the
membrane for their functional association with specific
targets [5]. Some PH domains have recently been shown
to bind specifically to phosphoinositides and disruption of
binding leads to loss of function; for example, Btk binds to
both phosphoinositides [6] and IP4 [7] through this
domain, as determined by mutagenesis.
Initially, we cloned the full-length GAP1m cDNA into
the pGEX4T-2 expression vector but were unable, under
the conditions described in the Materials and methods,
to isolate sufficient protein for binding analysis; however,
a deletion mutant in which the C2A and C2B domains
were removed (∆C2GAP1m) was found to be more
soluble and allowed easy purification of the resultant
fusion protein. As shown in Figure 1b, ∆C2GAP1m bound
to IP4 with high affinity (a Kd of 48.6 ± 1.6 nM) and speci-
ficity [Kd for Ins(1,3,4,5,6)P5, InsP6 and Ins(1,4,5)P3 of
453.3 ± 12.5, 691.7 ± 73.1 and > 10,000 nM, respectively].
The corresponding GAP1IP4BP deletion mutant
(∆C2GAP1IP4BP) bound to IP4 with similar affinity and
specificity to that of  ∆C2GAP1m [Kd for IP4,
Ins(1,3,4,5,6)P5, InsP6 and Ins(1,4,5)P3 of 30.8 ± 1.5, 450.7
± 56.2, 946.7 ± 22.5 and > 10,000 nM, respectively], sug-
gesting that GAP1m does indeed constitute a specific IP4-
binding protein. It should be stressed, however, that
unlike expressed full-length GAP1IP4BP, which has a Kd
for IP4 of 12.1 ± 2.9 nM compared with 9.3 ± 0.7 nM for
GAP1IP4BP purified from pig platelets (J.R.B. and P.J.C.,
unpublished observations), the binding of IP4 to either
expressed full-length or purified GAP1m has yet to be
characterised. The exact affinity and specificity of IP4
binding to GAP1m will be fully characterised only when
GAP1m purification is achieved. Our data are similar to
those of Fukuda and Mikoshiba [8] who have analysed
IP4 binding to ∆C2GAP1m from mouse brain; moreover,
they have shown that a point mutation within the PH
domain of GAP1m (Arg628→Cys) inhibits both IP4
binding and phospholipid binding in vitro.
Expression of GAP1IP4BP and GAP1m constructs was checked
by transiently transfecting COS-7 cells followed by
immunoblotting with specific anti-peptide antibodies.
Western blotting of a whole cell lysate 48 hours after trans-
fection showed the presence of proteins of the predicted
molecular weight and, furthermore, confirmed that there
was no cross-reactivity between the anti-GAP1IP4BP and anti-
GAP1m antibodies (data not shown). Expression and
immunocytochemical analyses of GAP1IP4BP in either COS-7
or HeLa cells — both of which contain endogenous
GAP1IP4BP and GAP1m as determined by reverse transcrip-
tion (RT)–PCR analysis — demonstrated a discrete
plasma membrane localisation (Figure 2a), which was con-
firmed independently by analysis of the expression of a
green fluorescent protein — GAP1IP4BP fusion protein
(GFP–GAP1IP4BP) in live cells (data not shown). In contrast,
immunocytochemical analysis of COS-7 cells expressing
GAP1m showed a predominantly perinuclear localisation of
the protein, in addition to a small cytoplasmic pool
(Figure 2b). The cytoplasmic localisation may be an artefact
of overexpression, although it is entirely consistent with the
original purification of GAP1m from both particulate and
cytoplasmic fractions [9]. The subcellular localisation of
GAP1m was confirmed using GFP–GAP1m (data not shown).
Furthermore, in both COS-7 and HeLa cells, the discrete
subcellular distribution of the two GAPs was observed even
upon coexpression of both GAPs (Figure 2c). 
To understand the mechanism underlying this difference
in subcellular localisation, we initially constructed a
GFP–GAP1IP4BP deletion mutant in which both the C2A and
C2B domains were removed (GFP–∆C2GAP1IP4BP). As can
been seen in Figure 3a, this deletion had no effect on the
plasma membrane localisation of GAP1IP4BP. Specific point
mutations within the PH domain of full-length GAP1IP4BP
(Lys599→Gln, Lys600→Gln, Arg601→Gln), however, had
the dual effect of completely abolishing IP4 binding (J.R.B.
and P.J.C., unpublished observations) resulting in a com-
plete loss of plasma membrane localisation (Figure 3b). This
suggests that the PH domain of GAP1IP4BP constitutes both
an IP4-binding and a phospholipid-binding site and that,
functionally, the two binding sites may overlap. This has an
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Figure 1
(a) Diagram of GAP1IP4BP and of GAP1m
showing the major structural features of the
GAPs and their identity between domains. (b)
Ins(1,3,4,5)P4 binding to ∆C2GAP1m
compared with that of ∆C2GAP1IP4BP (inset).
Binding was performed as described in
Material and methods. Each data point is from
three independent determinations; similar
results were obtained from two other
purifications. From the average of each
determination, Scatchard analysis revealed, in
both proteins, a single class of binding site
(data not shown). The affinities for IP4 detailed
in the text are the average of the resultant
three independent Scatchard analyses. 
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important physiological consequence, as it suggests that a
competition between the binding of phospholipids and of
IP4 to the PH domain may occur in vivo, such that an eleva-
tion of intracellular IP4 concentration may displace
GAP1IP4BP from the plasma membrane.
One obvious difference between the GAP1m and
GAP1IP4BP proteins is the alanine-rich 26 amino acid
amino-terminal extension in GAP1m. It is possible that
this may constitute an endoplasmic reticulum (ER) reten-
tion signal. Expression of a GAP1m construct, in which the
first 30 amino acids have been deleted, however, gave a
similar subcellular distribution to that of wild-type GAP1m
(data not shown). Furthermore, expression of a construct
containing the first 58 residues of GAP1m fused to GFP at
the carboxyl terminus produced a diffuse fluorescence
throughout the cytoplasm and nucleus (data not shown),
consistent with this motif having no role in ER targeting.
The subcellular localisation of GAP1m has intriguing
implications for the physiological function of IP4. We and
others have previously suggested that one function of IP4
may be to regulate communication between heteroge-
neous intracellular Ca2+ pools, and, indeed, a role for GTP
in such an event has been suggested from work by the
groups of Gill [10] and Dawson [11]. Thus, the possibility
exists that IP4 may function to regulate such an event
through its ability to bind at the ER, where an isoform of
the Ins(1,4,5)P3 3′-kinase also resides [12]. One question
raised by this particular localisation concerns the small
GTP-binding protein that is the physiological substrate
for GAP1m: GAP1m has been biochemically characterised
as a GAP for Ras in vitro [13], but its perinuclear localisa-
tion would suggest that it may not interact with the active
plasma membrane-targeted Ras in vivo unless a receptor-
mediated translocation event occurs.
In summary, the data described above highlight, for the
first time, a real biochemical distinction between the two
putative IP4 receptors, GAP1IP4BP and GAP1m. Of particular
interest is the observation that plasma membrane targeting
of GAP1IP4BP is mediated by the PH domain through a
motif that constitutes the IP4-binding site, suggesting that
the localisation and function of GAP1IP4BP might be regu-
lated by the competition between phospholipid binding
and IP4 binding. The perinuclear localisation of GAP1m has
not been observed before and is likely to have important
physiological consequences for the action of IP4.
Materials and methods
Materials
[32P]IP4 was prepared as previously described [14]. Chemicals were
from Sigma unless otherwise stated, and all tissue culture media and
reagents were from Gibco BRL.
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Figure 2
Indirect immunofluoresence and visualisation
of green fluorescent protein (GFP) in COS-7
and HeLa cells 48 h after transient
transfection with GAP1m and GAP1IP4BP.
(a) Expression of GAP1IP4BP in COS-7 cells
detected with H113 antiserum (1:200) and
anti-rabbit IgG TRITC conjugate. 
(b) Expression of GAP1m in COS-7 cells
detected with K45 antiserum (1:200) and
anti-rabbit IgG TRITC conjugate. 
(c) Coexpression of GFP–GAP1IP4BP and
GAP1m in fixed HeLa cells, GAP1m was
detected with K45 antiserum (1:200) and
anti-rabbit TRITC conjugate. Identical data to
those in (a) and (b) were obtained using GFP
constructs. Fixation and imaging were
performed as described in Materials and
methods.
Figure 3
Indirect immunofluorescence and GFP visualisation of COS-7 and
HeLa cells 48 hours after transient transfection with GAP1IP4BP
mutants. (a) Expression of GFP–∆C2GAP1IP4BP in live HeLa cells. 
(b) Expression of GAP1IP4BP (Lys599→Gln, Lys600→Gln,
Arg601→Gln) mutant in COS-7 detected with H113 antiserum
(1:200) and anti-rabbit IgG TRITC conjugate. Fixation and imaging
were performed as described in Materials and methods.
Cloning of GAP1m
Homologous primers (sense 5′-CAGGAGACTGGTGAAAAC-3′ and
antisense 5′-TGGATTTTCCTTGCTCCC-3′) were used to amplify a
348 bp fragment by PCR from a human circulating-blood cDNA library
(Stratagene No. 938202; oligo dT-primed and random-primed). After
four rounds of screening three independent clones were isolated and
excised in vivo into the pBK-CMV phagemid. One of these clones
(PJC-5), thought likely to be full-length after restriction mapping, was
sequenced on both strands using internal oligonucleotide primers on
an Applied Biosystems automated DNA sequencer. The predicted
open reading frame of 2547 bp encoded a 849 amino-acid protein
with a predicted molecular mass of 96,500 Da.
Cloning and mutagenesis procedures
The various constructs used in this study were produced by the
ExpandTM High Fidelity PCR system (Boehringer) with primers designed
to amplify the required fragment of cDNA. All constructs were
sequenced prior to use. Vectors used for mammalian gene expression
were pCI-neo (Promega) and pEGFP (Clontech), and GST constructs
were made in pGEX vectors (Pharmacia). Site-directed mutagenesis of
GAP1IP4BP was performed with the TransformerTM kit (Clontech). More
details of the cloning and mutagenesis are available as supplementary
information linked to the internet version of the paper.
Preparation of GAP1m (K45) and GAP1IP4BP (H113)
antiserum
The peptide SSSAKYGSKENPIVGKIS (which corresponds to the
carboxyl terminus of rat brain GAP1m [15]) was conjugated to
bovine purified protein derivative using sulfosuccinimidyl 4-[N-
maleimidomethyl]-cyclohexane-1-carboxylate (Sulfo-SMCC), mixed
with Freund’s adjuvant and injected into a rabbit. Anti-GAP1IP4BP
antisera were isolated as previously described [1].
Indirect immunofluorescence
Transfected cells were fixed in ice-cold PBS followed by immersion in
70% acetone/30% methanol for 10 min. Primary antibody was diluted
to the desired concentration in PBS–Triton X-100 (0.1% v/v). Cover-
slips were soaked in PBS–Triton for 15 min prior to incubation with
primary antibody for 1 h at 37°C. After the incubation, each coverslip
was rinsed twice in PBS–Triton for 15 min with gentle agitation. The
second antibody, anti-rabbit IgG (whole molecule) TRITC conjugate
diluted in PBS–Triton (1:200), was added and incubated at 37°C for
1 hr. Coverslips were rinsed twice for 15 mins in PBS-Triton and
mounted on glass microscope slides in 60% (v/v) glycerol/2.5% (w/v)
1,4-diazabicyclo-[2.2.2]octane. Immunofluorescence staining was visu-
alised by a Leica TCS-NT confocal laser-scanning microscope
equipped with a Kr/Ar laser. The confocal was attached to a Leica DM
RBE upright epifluorescence microscope. GFP fluorescence in live
cells was visualised using an identical system attached to an inverted
microscope.
Expression of GST–∆C2GAP1m and GST–∆C2GAP1IP4BP
constructs in Escherichia coli
E. coli strain BL-21 expressing GroES/L chaperonins was transformed
with pGEX–∆C2GAP1m or pGEX–∆C2GAP1IP4BP. Each resultant
GST fusion was isolated by incubation with glutathione sepharose 4B
resin (Pharmacia Biotech) according to the manufacturer’s instructions.
IP4-binding assays were performed as previously described [14].
Supplementary material
Further details on cloning, mutagenesis and cell culture are published
with this paper on the internet.
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